Cargando…
Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia
INTRODUCTION: Upfront next-generation sequencing (NGS) in patients with metastatic NSCLC has been associated with cost savings and shorter time-to-test results in the United States. Nevertheless, this may not apply in jurisdictions where the prevalence of patients with actionable mutations, cost of...
Autores principales: | Loong, Herbert H., Wong, Carlos K.H., Chan, Catherine P.K., Chang, Andrea, Zhou, Zheng-Yi, Tang, Wenxi, Gibbs, Meaghan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919283/ https://www.ncbi.nlm.nih.gov/pubmed/35295964 http://dx.doi.org/10.1016/j.jtocrr.2022.100290 |
Ejemplares similares
-
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2020) -
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice
por: Cho, Byoung Chul, et al.
Publicado: (2022) -
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer
por: Kuang, Shelley, et al.
Publicado: (2022) -
Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
por: Tjong, Michael C., et al.
Publicado: (2021) -
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
por: Xia, Bing, et al.
Publicado: (2020)